Lars Fruergaard Jørgensen, Novo Nordisk CEO (Chris Ratcliffe/Bloomberg via Getty Images)

No­vo Nordisk con­tin­ues di­a­betes, obe­si­ty sales rise, but still on the back foot with We­govy sup­ply

As de­mand for No­vo Nordisk’s GLP-1 prod­ucts con­tin­ues un­abat­ed, all eyes are on the phar­ma gi­ant to meet de­mand.

Start­ing this month, No­vo has more …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.